The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis
Open Access
- 10 May 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 39 (12) , 2040-2047
Abstract
Background: Chronic kidney disease (CKD) presents a significant clinical and economic burden to healthcare systems worldwide, which increases considerably with progression towards kidney failure. The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial demonstrated that patients with or without type 2 diabetes who were treated with dapagliflozin experienced slower progression of CKD versus those receiving placebo. Understanding the effect of long-term treatment with dapagliflozin on the timing of kidney failure beyond trial follow-up can assist informed decision-making by healthcare providers and patients. The study objective was therefore to extrapolate the outcome-based clinical benefits of treatment with dapagliflozin in patients with CKD via a time-to-event analysis using trial data. Methods: Patient-level data from the DAPA-CKD trial were used to parameterize a closed cohort-level partitioned survival model that predicted time-to-event for key trial endpoints (kidney failure, all-cause mortality, sustained decline in kidney function and hospitalization for heart failure). Data were pooled with a subpopulation of the Dapagliflozin Effect on Cardiovascular Events – Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial to create a combined CKD population spanning a range of CKD stages; a parallel survival analysis was conducted in this population. Results: In the DAPA-CKD and pooled CKD populations, treatment with dapagliflozin delayed time to first event for kidney failure, all-cause mortality, sustained decline in kidney function and hospitalization for heart failure. Attenuation of CKD progression was predicted to slow the time to kidney failure by 6.6 years [dapagliflozin: 25.2, 95% confidence interval (CI) 19.0–31.5; standard therapy: 18.5, 95% CI 14.7–23.4] in the DAPA-CKD population. A similar result was observed in the pooled CKD population with an estimated delay of 6.3 years (dapagliflozin: 36.0, 95% CI 31.9–38.3; standard therapy: 29.6, 95% CI 25.5–34.7). Conclusion: Treatment with dapagliflozin over a lifetime time horizon may considerably delay the mean time to adverse clinical outcomes for patients who would go on to experience them, including those at modest risk of progression.Keywords
Funding Information
- AstraZeneca
This publication has 27 references indexed in Scilit:
- A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionKidney International, 2022
- Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection FractionJAMA Cardiology, 2021
- Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?Value in Health, 2020
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Prevalence and Disease Burden of Chronic Kidney Disease2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Reducing the costs of chronic kidney disease while delivering quality health care: a call to actionNature Reviews Nephrology, 2017
- The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology careKidney International, 2012
- A Predictive Model for Progression of Chronic Kidney Disease to Kidney FailureJAMA, 2011